<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532973</url>
  </required_header>
  <id_info>
    <org_study_id>8742-002</org_study_id>
    <secondary_id>2011-005190-23</secondary_id>
    <nct_id>NCT01532973</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetics (PK) and pharmacodynamics
      of elbasvir (MK-8742) in Hepatitis C Virus (HCV)-infected participants. There will be 3 parts
      to this study; Part I will enroll only genotype (GT) 1 HCV-infected participants, Part II
      will enroll GT3 HCV-infected participants, and Part III will enroll only GT1a HCV-infected
      participants. All parts may run concurrently, or Parts II and III may be staggered.

      Hypothesis (Part I): At a once-daily dose that is sufficiently safe and well tolerated in
      HCV-infected participants, elbasvir administered for 5 consecutive days has superior
      antiviral activity in GT1 HCV-infected participants compared to placebo, as measured by
      change from baseline in plasma HCV ribonucleic acid (RNA; log 10 copies/mL) at Day 5, 24-hour
      postdose timepoint. (a true mean viral RNA reduction of at least 3 log10 is anticipated).

      Hypothesis (Part II): At a dose that is sufficiently safe in GT3 HCV-infected participants,
      the mean maximum reduction in HCV viral load is greater following multiple dose oral
      administration of elbasvir as compared to placebo.

      Hypothesis (Part III): At a once-daily dose that is sufficiently safe and well tolerated in
      HCV-infected participants, elbasvir administered for 5 consecutive days has superior
      antiviral activity in GT1a HCV-infected participants compared to placebo, as measured by
      change from baseline in plasma HCV RNA (log 10 copies/mL) at Day 5, 24-hour postdose
      timepoint. (a true mean viral RNA reduction of at least 3 log10 is anticipated).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1</measure>
    <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT3</measure>
    <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT1a</measure>
    <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT3</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1a</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing an Adverse Event (AE) - Day 1 to Day 5</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Participants who had study drug discontinued due to an AE were recorded.</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hepatitis, Viral, Human</condition>
  <arm_group>
    <arm_group_label>GT1 HCV 10-mg Elbasvir (Panel A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GTI HCV 50-g Elbasvir (Panel B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1 HCV 5-mg Elbavir (Panel C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1 HCV 200-mg Elbasvir (Panel D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3 HCV 10-mg Elbasvir (Panel E)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3 HCV 50-mg Elbasvir (Panel F)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3 HCV 100-mg Elbasvir (Panel G)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3 HCV 200-mg Elbasvir (Panel H)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1a HCV 10-mg Elbasvir (Panel I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1a HCV 50-mg Elbasvir (Panel J)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir</intervention_name>
    <description>Elbasvir was administered orally by tablet(s)</description>
    <arm_group_label>GT1 HCV 10-mg Elbasvir (Panel A)</arm_group_label>
    <arm_group_label>GTI HCV 50-g Elbasvir (Panel B)</arm_group_label>
    <arm_group_label>GT1 HCV 5-mg Elbavir (Panel C)</arm_group_label>
    <arm_group_label>GT1 HCV 200-mg Elbasvir (Panel D)</arm_group_label>
    <arm_group_label>GT3 HCV 10-mg Elbasvir (Panel E)</arm_group_label>
    <arm_group_label>GT3 HCV 50-mg Elbasvir (Panel F)</arm_group_label>
    <arm_group_label>GT3 HCV 100-mg Elbasvir (Panel G)</arm_group_label>
    <arm_group_label>GT3 HCV 200-mg Elbasvir (Panel H)</arm_group_label>
    <arm_group_label>GT1a HCV 10-mg Elbasvir (Panel I)</arm_group_label>
    <arm_group_label>GT1a HCV 50-mg Elbasvir (Panel J)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose-matched placebo tablets were administered orally.</description>
    <arm_group_label>GT1 HCV 10-mg Elbasvir (Panel A)</arm_group_label>
    <arm_group_label>GTI HCV 50-g Elbasvir (Panel B)</arm_group_label>
    <arm_group_label>GT1 HCV 5-mg Elbavir (Panel C)</arm_group_label>
    <arm_group_label>GT1 HCV 200-mg Elbasvir (Panel D)</arm_group_label>
    <arm_group_label>GT3 HCV 10-mg Elbasvir (Panel E)</arm_group_label>
    <arm_group_label>GT3 HCV 50-mg Elbasvir (Panel F)</arm_group_label>
    <arm_group_label>GT3 HCV 100-mg Elbasvir (Panel G)</arm_group_label>
    <arm_group_label>GT3 HCV 200-mg Elbasvir (Panel H)</arm_group_label>
    <arm_group_label>GT1a HCV 10-mg Elbasvir (Panel I)</arm_group_label>
    <arm_group_label>GT1a HCV 50-mg Elbasvir (Panel J)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 18 to ≤ 37 kg/m^2

          -  Clinical diagnosis of chronic HCV infection defined by positive serology for HCV for
             at least 6 months and detectable HCV RNA in peripheral blood ≥105 IU/mL at screening

          -  Participant must be infected with HCV GT1a, GT1b, or GT 3

        Exclusion Criteria:

          -  Co-infection with GT1 and GT3

          -  Estimated creatinine clearance of ≤70 mL/min based on the Cockcroft-Gault equation

          -  History of stroke, chronic seizures, or major neurological disorder

          -  History of clinically significant endocrine, gastrointestinal (excepting HCV
             infection), cardiovascular, hematological, immunological, renal, respiratory, or
             genitourinary abnormalities or diseases

          -  History of neoplastic disease

          -  Positive Hepatitis B surface antigen at the pre-study (screening) visit

          -  Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or
             participated in another investigational study within 4 weeks prior to the prestudy
             (screening) visit.

          -  Previous treatments (s) with nonstructural protein 5A (NS5A) inhibitors

          -  &lt;4 weeks since administration of any experimental protease inhibitor

          -  Previous exposure to interferon-alpha and/or ribavirin within 3 month prior to the
             first dose of elbasvir in the study

          -  Clinical or laboratory evidence of advanced or decompensated liver disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
  </removed_countries>
  <reference>
    <citation>Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9. doi: 10.1128/AAC.01390-15. Epub 2015 Aug 24.</citation>
    <PMID>26303801</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>October 3, 2016</results_first_submitted>
  <results_first_submitted_qc>October 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 23, 2016</results_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Viral, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 Panels (Panel D in Part 1 and Panel H in Part 2) were planned but not performed. No participants were enrolled in either of these panels.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GT1 HCV 10-mg Elbasvir (Panel A)</title>
          <description>Participants with genotype (GT) 1 hepatitis C virus (HCV) receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="P2">
          <title>GT1 HCV 50-g Elbasvir (Panel B)</title>
          <description>Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="P3">
          <title>GT1 HCV 5-mg Elbasvir (Panel C)</title>
          <description>Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="P4">
          <title>GT1 HCV 200-mg Elbasvir (Panel D)</title>
          <description>Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="P5">
          <title>GT3 HCV 10-mg Elbasvir (Panel E)</title>
          <description>Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="P6">
          <title>GT3 HCV 50-mg Elbasvir (Panel F)</title>
          <description>Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="P7">
          <title>GT3 HCV 100-mg Elbasvir (Panel G)</title>
          <description>Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="P8">
          <title>GT3 HCV 200-mg Elbasvir (Panel H)</title>
          <description>Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="P9">
          <title>GT1a HCV 10-mg Elbasvir (Panel I)</title>
          <description>Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
        </group>
        <group group_id="P10">
          <title>GT1a HCV 50-mg Elbasvir (Panel J)</title>
          <description>Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0">Planned panel not performed. No participants were enrolled.</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0">Planned panel not performed. No participants were enrolled.</participants>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants who received at least one dose of study drug. Participants who received placebo in Part 1, 2, or 3 are grouped together regardless of HCV GT or randomly assigned panel. 2 Panels (Panel D in Part 1 and Panel H in Part 2) were planned but not performed. No participants were enrolled in either of these panels.</population>
      <group_list>
        <group group_id="B1">
          <title>GT1 HCV 10-mg Elbasvir (Panel A)</title>
          <description>Participants with GT1 Hepatitis who received 10 -mg elbasvir for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="B2">
          <title>GT1 HCV 50-g Elbasvir (Panel B)</title>
          <description>Participants with GT1 HCV receive 50-mg elbasvir for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="B3">
          <title>GT1 HCV 5-mg Elbasvir (Panel C)</title>
          <description>Participants with GT1 HCV receive 5-mg elbasvir for 5 consecutive days during Part I of the study.</description>
        </group>
        <group group_id="B4">
          <title>GT3 HCV 10-mg Elbasvir (Panel E)</title>
          <description>Participants with GT3 HCV receive 10-mg elbasvir for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="B5">
          <title>GT3 HCV 50-mg Elbasvir (Panel F)</title>
          <description>Participants with GT3 HCV receive 50-mg elbasvir for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="B6">
          <title>GT3 HCV 100-mg Elbasvir (Panel G)</title>
          <description>Participants with GT3 HCV receive 100-mg elbasvir for 5 consecutive days during Part II of the study.</description>
        </group>
        <group group_id="B7">
          <title>GT1a HCV 10-mg Elbasvir (Panel I)</title>
          <description>Participants with GT1a only HCV receive 10-mg elbasvir for 5 consecutive days during Part III of the study.</description>
        </group>
        <group group_id="B8">
          <title>GT1a HCV 50-mg Elbasvir (Panel J)</title>
          <description>Participants with GT1a only HCV receive 50-mg elbasvir for 5 consecutive days during Part III of the study.</description>
        </group>
        <group group_id="B9">
          <title>Placebo</title>
          <description>Participants with GT1, GT3 or GT1a HCV who received placebo in Parts I, II, or II of the study.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="5"/>
            <count group_id="B8" value="5"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="10.8"/>
                    <measurement group_id="B2" value="36.8" spread="6.9"/>
                    <measurement group_id="B3" value="51.6" spread="8.8"/>
                    <measurement group_id="B4" value="34.8" spread="6.4"/>
                    <measurement group_id="B5" value="35.8" spread="8.9"/>
                    <measurement group_id="B6" value="34.6" spread="6.8"/>
                    <measurement group_id="B7" value="51.0" spread="5.0"/>
                    <measurement group_id="B8" value="53.2" spread="11.6"/>
                    <measurement group_id="B9" value="47.8" spread="10.8"/>
                    <measurement group_id="B10" value="43.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1</title>
        <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
        <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel D was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1 HCV 10-mg Elbasvir (Panel A)</title>
            <description>Participants with GT1 Hepatitis receive 10 -mg elbasvir for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT1 HCV 50-g Elbasvir (Panel B)</title>
            <description>Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O3">
            <title>GT1 HCV 5-mg Elbasvir (Panel C)</title>
            <description>Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction From Baseline in Log10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 5 - HCV GT1</title>
          <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel D was not conducted.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.80" upper_limit="4.71"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.95" upper_limit="4.86"/>
                    <measurement group_id="O3" value="3.56" lower_limit="3.10" upper_limit="4.02"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.37" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>4.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.77</ci_lower_limit>
            <ci_upper_limit>4.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>4.41</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.92</ci_lower_limit>
            <ci_upper_limit>4.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.08</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT3</title>
        <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction</description>
        <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel H was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>GT3 HCV 10-mg Elbasvir (Panel E)</title>
            <description>Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT3 HCV 50-mg Elbasvir (Panel F)</title>
            <description>Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>GT3 HCV 100-mg Elbasvir (Panel G)</title>
            <description>Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT3</title>
          <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel H was not conducted.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.38" upper_limit="1.65"/>
                    <measurement group_id="O2" value="2.06" lower_limit="1.43" upper_limit="2.70"/>
                    <measurement group_id="O3" value="2.72" lower_limit="2.08" upper_limit="3.35"/>
                    <measurement group_id="O4" value="0.00" lower_limit="-0.50" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>2.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>2.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT1a</title>
        <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
        <time_frame>Baseline (Predose on Day 1) and 24-hour post-dose on Day 5</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1a HCV 10-mg Elbasvir (Panel I)</title>
            <description>Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT1a HCV 50-mg Elbasvir (Panel J)</title>
            <description>Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction From Baseline in Log10 Plasma HCV RNA at Day 5 - HCV GT1a</title>
          <description>HCV RNA levels were assessed at baseline (predose on Day 1) and 24 hours postdose on Day 5 using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. Least squares means and confidence intervals obtained from the linear mixed model with log10 HCV RNA reduction as response and a fixed effect for treatment, time and treatment by time interaction.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="2.71" upper_limit="3.68"/>
                    <measurement group_id="O2" value="3.95" lower_limit="3.46" upper_limit="4.43"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.39" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.68</ci_lower_limit>
            <ci_upper_limit>3.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.44</ci_lower_limit>
            <ci_upper_limit>4.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1</title>
        <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel D was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1 HCV 10-mg Elbasvir (Panel A)</title>
            <description>Participants with GT1 Hepatitis receive 10 -mg elbasvir for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT1 HCV 50-g Elbasvir (Panel B)</title>
            <description>Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O3">
            <title>GT1 HCV 5-mg Elbasvir (Panel C)</title>
            <description>Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1</title>
          <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel D was not conducted.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" lower_limit="3.78" upper_limit="5.09"/>
                    <measurement group_id="O2" value="5.21" lower_limit="4.56" upper_limit="5.87"/>
                    <measurement group_id="O3" value="4.15" lower_limit="3.50" upper_limit="4.81"/>
                    <measurement group_id="O4" value="0.54" lower_limit="0.03" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.20</ci_lower_limit>
            <ci_upper_limit>4.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>4.67</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.98</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.92</ci_lower_limit>
            <ci_upper_limit>4.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT3</title>
        <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel H was not conducted.</population>
        <group_list>
          <group group_id="O1">
            <title>GT3 HCV 10-mg Elbasvir (Panel E)</title>
            <description>Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT3 HCV 50-mg Elbasvir (Panel F)</title>
            <description>Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O3">
            <title>GT3 HCV 100-mg Elbasvir (Panel G)</title>
            <description>Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT3</title>
          <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel. Panel H was not conducted.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="0.49" upper_limit="2.04"/>
                    <measurement group_id="O2" value="3.12" lower_limit="2.34" upper_limit="3.89"/>
                    <measurement group_id="O3" value="3.38" lower_limit="2.61" upper_limit="4.16"/>
                    <measurement group_id="O4" value="0.54" lower_limit="-0.07" upper_limit="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.72</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>2.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.75</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>2.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.02</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1a</title>
        <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1a HCV 10-mg Elbasvir (Panel I)</title>
            <description>Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
          </group>
          <group group_id="O2">
            <title>GT1a HCV 50-mg Elbasvir (Panel J)</title>
            <description>Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Maximum Reduction in Log10 HCV Viral Load - HCV GT1a</title>
          <description>HCV RNA levels were assessed at baseline (predose Day 1) and 24 hours postdose on Days 1-5. using the Roche TaqMan HCV 2.0 assay and transformed to Log10 values. The lower limits of quantification (LLOQ) and detection (LLD) were 25 and 9.3 IU/mL, respectively. The change in log10 LS mean HCV RNA levels was calculated for each timepoint and the maximum change from baseline was recorded.</description>
          <population>All participants who complied with the protocol sufficiently to ensure that data would likely exhibit the effects of treatment, according to the underlying scientific model and had available data from at least 1 treatment. Data for placebo were grouped together regardless of genotype or randomly assigned panel.</population>
          <units>IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" lower_limit="3.12" upper_limit="4.31"/>
                    <measurement group_id="O2" value="4.17" lower_limit="3.57" upper_limit="4.77"/>
                    <measurement group_id="O3" value="0.54" lower_limit="0.07" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.55</ci_lower_limit>
            <ci_upper_limit>3.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>3.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.00</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing an Adverse Event (AE) - Day 1 to Day 5</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who received at least 1 dose of study drug. Events reported by drug taken at time of event and not by panel or genotype</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Elbasvir</title>
            <description>Participants with HCV GT1 who received 5 -mg elbasvir</description>
          </group>
          <group group_id="O2">
            <title>10-g Elbasvir</title>
            <description>Participants with HCV GT1, GT3, or GT1a who received 10-mg elbasvir</description>
          </group>
          <group group_id="O3">
            <title>50-mg Elbasvir</title>
            <description>Participants with HCV GT1, GT3, or GT1a who received 50-mg elbasvir</description>
          </group>
          <group group_id="O4">
            <title>100-mg Elbasvir</title>
            <description>Participants with HCV GT3 who received 100-mg elbasvir</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing an Adverse Event (AE) - Day 1 to Day 5</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE.</description>
          <population>All participants who received at least 1 dose of study drug. Events reported by drug taken at time of event and not by panel or genotype</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Participants who had study drug discontinued due to an AE were recorded.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who received at least 1 dose of study drug. Event summarized by drug taken at time of event and not by panel or genotype</population>
        <group_list>
          <group group_id="O1">
            <title>5-mg Elbasvir</title>
            <description>Participants with HCV GT1 who received 5 -mg elbasvir</description>
          </group>
          <group group_id="O2">
            <title>10-g Elbasvir</title>
            <description>Participants with HCV GT1, GT3, or GT1a who received 10-mg elbasvir</description>
          </group>
          <group group_id="O3">
            <title>50-mg Elbasvir</title>
            <description>Participants with HCV GT1, GT3, or GT1a who received 50-mg elbasvir</description>
          </group>
          <group group_id="O4">
            <title>100-mg Elbasvir</title>
            <description>Participants with HCV GT3 who received 100-mg elbasvir</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Participants with HCV GT1, GT3 or GT1a who received placebo during Parts I, II, or III of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Study Drug Discontinued Due to an Adverse Event</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Participants who had study drug discontinued due to an AE were recorded.</description>
          <population>All participants who received at least 1 dose of study drug. Event summarized by drug taken at time of event and not by panel or genotype</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1 to 5 for each panel and then up to 56 days post last dose for follow-up period</time_frame>
      <desc>Adverse events are reported by drug taken at time of event for Days1-5 and not by panel or genotype. Adverse events for the post-study follow-up period (Days 6 to 61) are reported as 1 group regardless of genotype or study drug or dose received.</desc>
      <group_list>
        <group group_id="E1">
          <title>5-mg Elbasvir</title>
          <description>Participants with HCV GT1 who received 5 -mg elbasvir</description>
        </group>
        <group group_id="E2">
          <title>10-g Elbasvir</title>
          <description>Participants with HCV GT1, GT3, or GT1a who received 10-mg elbasvir</description>
        </group>
        <group group_id="E3">
          <title>50-mg Elbasvir</title>
          <description>Participants with HCV GT1, GT3, or GT1a who received 50-mg elbasvir</description>
        </group>
        <group group_id="E4">
          <title>100-mg Elbasvir</title>
          <description>Participants with HCV GT3 who received 100-mg elbasvir</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants with HCV GT1, GT3 or GT1a who received placebo during.</description>
        </group>
        <group group_id="E6">
          <title>Post-Study</title>
          <description>All participants who received 5, 10, 50, or 100 mg of elbasvir or placebo in treatment period of study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication timelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

